Abstract | UNLABELLED: AIM: METHODS: We retrospectively analysed 73 patients diagnosed with low-grade follicular lymphoma treated with two different schemes: attenuated oral (AO) and standard intravenous (SIV) FCR. RESULTS: Overall response rate (ORR) was 95% (complete response rate, CRR 79.5%, partial response, PR 15.4%). CRR was 84.6% in AO vs. 61.9% in SIV (P = 0.058). 44.4% of patients underwent maintenance therapy. Grade 3-4 toxicities included neutropenia: 65.4%; anaemia: 39.7%; thrombocytopenia: five patients; infectious complications: six patients. There were no treatment-related deaths. 6.8% had a secondary malignancy. Progression-free survival (PFS) was 84.6% at 12 yr. The following variables influenced PFS in multivariate analysis: Hb < 12 g/dL [HR 4.7 (95% CI 1.18-18.6)], response after induction [HR 4.9 (95% CI 1.01-24)] for PR vs. CR and [HR 21.27 (95% CI 4.33-104)] for SD/DP vs. CR. OS was 83.1% at 12 yr. The following variables significantly influenced OS in multivariate analysis: not receiving rituximab as maintenance therapy (HR 10.7 (95% CI 1.4-82.5), increased levels of β2-microglobulin [HR 5.2 (95% CI 1.16-23.7)]. CONCLUSIONS: FCR allowed us to obtain a high response rate, which translated into promising progression free and overall survival with an acceptable and manageable toxicity profile, especially with the attenuated oral scheme.
|
Authors | Fátima De la Cruz Vicente, Estrella Carrillo-Cruz, Maria Sole Rodriguez, Ana Marín Niebla, Maria Luz Martino Galiana, Jose Falantes Gonzalez, Isabel Montero Cuadrado, Jose Gonzalez Campos, Ildefonso Espigado Tocino, Eduardo Rios-Herranz, Jose Antonio Perez-Simón |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 93
Issue 6
Pg. 469-75
(Dec 2014)
ISSN: 1600-0609 [Electronic] England |
PMID | 24853381
(Publication Type: Journal Article)
|
Copyright | © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Rituximab
- Cyclophosphamide
- Vidarabine
- fludarabine
|
Topics |
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cyclophosphamide
(administration & dosage)
- Female
- Humans
- Lymphoma, Follicular
(diagnosis, drug therapy, mortality)
- Male
- Neoplasm Grading
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Retrospective Studies
- Rituximab
- Treatment Outcome
- Vidarabine
(administration & dosage, analogs & derivatives)
|